NICO Corporation, a company based in Indianapolis, Indiana, is releasing its new NICO Myriad NOVUS resection tool. The FDA cleared product combines xenon illumination with NICO’s proven myriad neural tissue removal technology.
Xenon lights reproduce the visible spectrum of daylight much better than most other bulbs, although LED contenders are now available, and so are often the optimal choice when working in a confined environment and where precision is key.
The Myriad NOVUS is intended to help with intracerebral hemorrhage clot evacuation and subcortical tumor resection, whether using a microscope, surgical loupe, or an exoscope.
The company claims that it provides, “for the first time ever, automated & intraoperative tissue harvesting for post-procedural analysis in the modern molecular era. Its capabilities include illumination, identification, resection, tissue collection & preservation.”
“The ability to optimally see what we’re doing, to safely resect lesions, and to automatically obtain and preserve tissue for pathologic and molecular analyses has been greatly enhanced by the advent of the NOVUS platform from NICO,” said Dr. Mark Rosenblum, Chairman Emeritus, Department of Neurosurgery at Henry Ford Health System, in the announcement.
“The NOVUS represents the next generation of NICO’s flagship product the Myriad,” added Jim Pearson, President and CEO of NICO Corporation. “We are excited to give surgeons more versatility across minimally invasive port access, endoscopic, and skull base surgical approaches while still addressing their needs surrounding procedural efficiencies and convenience.”